Claim/exemption information - Registry number 3504911

Disclose a statement to the effect that the actual concentration is withheld as a trade secret, where prescribed concentration ranges are used.

Disclose all headings as set out in column 1 of Schedule 1, specifically “Identification” and “Other information”.

Disclose an adequate product odour.

Disclose the CAS registry number for “Exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate”, “4,4'-isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acid”, and “Ethoxylated Trimethylolpropane Triacrylate”.

Disclose the HMIRA registry number and correct date of decision granting the exemption, and clearly link which ingredients are part of the subject of the claim for exemption under the HMIRA. Additionally, remove the references to the HMIRA with respect to the subjects of the claim that are invalid.

Disclose the additional hazard classifications for the product (see appendix 1).

Disclose the appropriate hazard classification information for Skin Irritation - Category 2 and Serious Eye Damage – Category 1.

Disclose the common name and synonyms for the ingredients listed in section 3 of the SDS.

Disclose the correct and complete LD50 and LC50 values (see appendix 5).

Disclose the delayed and immediate effects, and chronic effects from short-term and long-term exposure.

Disclose the hazard statements for each of the product hazard classification categories or subcategories (see appendix 2).

Disclose the hazardous ingredients “Exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate”, “4,4'-isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane, esters with acrylic acid”, and “Ethoxylated Trimethylolpropane Triacrylate”.

Disclose the most important effects, whether acute or delayed in section 4 of the SDS.

Disclose the percent of unknown acute inhalation (dust/mist) toxicity (79.25%), and remove the misleading information regarding the percent of unknown acute toxicity.

Disclose the product oral and inhalation (dust/mist) acute toxicity estimates (ATEs) of 6,400 mg/kg and 1.3 mg/L (79.25% unknown), respectively, and remove the misleading information regarding the percent of unknown acute toxicity.

Disclose the relevant conditions for safe storage (see appendix 4).

Disclose the relevant first-aid measures (see appendix 3).

Disclose the relevant precautions for safe handling (see appendix 4).

Disclose the telephone number of the initial Canadian supplier(s).

Remove all forward slashes or diagonal marks in precautionary statements for which a choice is to be made.